当基于价值的定价不合适时，回报率定价是一种有用的方法吗？ - Suppr

Suppr

超能文献

Is rate of return pricing a useful approach when value-based pricing is not appropriate?

作者信息

Drummond Michael, Towse Adrian

机构信息

Centre for Health Economics, Alcuin 'A' Block, University of York, Heslington, York, YO10 5DD, UK.

Office of Health Economics, London, UK.

出版信息

Eur J Health Econ. 2019 Sep;20(7):945-948. doi: 10.1007/s10198-019-01032-7.

DOI:10.1007/s10198-019-01032-7

PMID:30771033

Abstract

摘要

相似文献

Is rate of return pricing a useful approach when value-based pricing is not appropriate?

Eur J Health Econ. 2019 Sep;20(7):945-948. doi: 10.1007/s10198-019-01032-7.

Steps toward transparency. Health organizations need to be open with consumers about pricing.

Mod Healthc. 2013 Jun 17;43(24):28.

Investor drought and regulatory headwinds slow device innovation.

Health Aff (Millwood). 2015 Feb;34(2):199-202. doi: 10.1377/hlthaff.2014.1442.

New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare-An Introduction.

Value Health. 2019 Jun;22(6S):S1-S3. doi: 10.1016/j.jval.2019.04.1912.

Biomedical innovation in the era of health care spending constraints.

Health Aff (Millwood). 2015 Feb;34(2):203-9. doi: 10.1377/hlthaff.2014.0975.

Toward a Hedonic Value Framework in Health Care.

Value Health. 2017 Feb;20(2):261-265. doi: 10.1016/j.jval.2016.11.022.

Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging.

Semin Musculoskelet Radiol. 2017 Feb;21(1):37-42. doi: 10.1055/s-0036-1597254. Epub 2017 Mar 2.

Affordability of New Technologies: The Next Frontier.

Value Health. 2018 Mar;21(3):249-251. doi: 10.1016/j.jval.2018.01.011. Epub 2018 Feb 19.

Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value.

Health Aff (Millwood). 2013 Apr;32(4):788-96. doi: 10.1377/hlthaff.2012.1210.

Current Policy and Practice for Value-Based Pricing.

Value Health. 2019 Jun;22(6S):S4-S6. doi: 10.1016/j.jval.2019.04.1918.

引用本文的文献

Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.

Appl Health Econ Health Policy. 2025 May;23(3):467-478. doi: 10.1007/s40258-024-00932-x. Epub 2024 Dec 2.

Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification.

Pharmacoeconomics. 2025 Jan;43(1):5-29. doi: 10.1007/s40273-024-01435-2. Epub 2024 Oct 15.

Unraveling elements of value-based pricing from a pharmaceutical industry's perspective: a scoping review.

Front Pharmacol. 2024 Jun 24;15:1298923. doi: 10.3389/fphar.2024.1298923. eCollection 2024.

Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review.

Pharmacoecon Open. 2024 Sep;8(5):765-772. doi: 10.1007/s41669-024-00496-5. Epub 2024 May 21.

Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?

Pharmacoeconomics. 2024 Aug;42(8):823-827. doi: 10.1007/s40273-024-01393-9. Epub 2024 May 11.

Market access and value-based pricing of digital health applications in Germany.

Cost Eff Resour Alloc. 2022 Jun 13;20(1):25. doi: 10.1186/s12962-022-00359-y.

An integrated valuation model for payer and investor.

J Mark Access Health Policy. 2022 May 29;10(1):2080631. doi: 10.1080/20016689.2022.2080631. eCollection 2022.

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Appl Health Econ Health Policy. 2022 Jul;20(4):501-524. doi: 10.1007/s40258-021-00714-9. Epub 2022 Apr 4.

How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations.

Value Health. 2021 Oct;24(10):1391-1399. doi: 10.1016/j.jval.2021.03.022. Epub 2021 Jul 30.

Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.

Eur J Health Econ. 2022 Mar;23(2):155-163. doi: 10.1007/s10198-021-01276-2. Epub 2021 Jun 9.

本文引用的文献

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.

Value-based differential pricing: efficient prices for drugs in a global context.

Health Econ. 2015 Mar;24(3):294-301. doi: 10.1002/hec.3021. Epub 2013 Dec 11.

What is wrong with orphan drug policies?

Value Health. 2012 Dec;15(8):1185-91. doi: 10.1016/j.jval.2012.09.004.

OFT, VBP: QED?

Health Econ. 2007 Jun;16(6):545-58. doi: 10.1002/hec.1249.

Orphan drugs and the NHS: should we value rarity?

BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016.

The role of economic evaluation in the pricing and reimbursement of medicines.

Health Policy. 1997 Jun;40(3):199-215. doi: 10.1016/s0168-8510(97)00901-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Is rate of return pricing a useful approach when value-based pricing is not appropriate?

Eur J Health Econ. 2019 Sep;20(7):945-948. doi: 10.1007/s10198-019-01032-7.

Steps toward transparency. Health organizations need to be open with consumers about pricing.

Mod Healthc. 2013 Jun 17;43(24):28.

Investor drought and regulatory headwinds slow device innovation.

Health Aff (Millwood). 2015 Feb;34(2):199-202. doi: 10.1377/hlthaff.2014.1442.

New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare-An Introduction.

Value Health. 2019 Jun;22(6S):S1-S3. doi: 10.1016/j.jval.2019.04.1912.

Biomedical innovation in the era of health care spending constraints.

Health Aff (Millwood). 2015 Feb;34(2):203-9. doi: 10.1377/hlthaff.2014.0975.

Toward a Hedonic Value Framework in Health Care.

Value Health. 2017 Feb;20(2):261-265. doi: 10.1016/j.jval.2016.11.022.

Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging.

Semin Musculoskelet Radiol. 2017 Feb;21(1):37-42. doi: 10.1055/s-0036-1597254. Epub 2017 Mar 2.

Affordability of New Technologies: The Next Frontier.

Value Health. 2018 Mar;21(3):249-251. doi: 10.1016/j.jval.2018.01.011. Epub 2018 Feb 19.

Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value.

Health Aff (Millwood). 2013 Apr;32(4):788-96. doi: 10.1377/hlthaff.2012.1210.

Current Policy and Practice for Value-Based Pricing.

Value Health. 2019 Jun;22(6S):S4-S6. doi: 10.1016/j.jval.2019.04.1918.

引用本文的文献

Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.

Appl Health Econ Health Policy. 2025 May;23(3):467-478. doi: 10.1007/s40258-024-00932-x. Epub 2024 Dec 2.

Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification.

Pharmacoeconomics. 2025 Jan;43(1):5-29. doi: 10.1007/s40273-024-01435-2. Epub 2024 Oct 15.

Unraveling elements of value-based pricing from a pharmaceutical industry's perspective: a scoping review.

Front Pharmacol. 2024 Jun 24;15:1298923. doi: 10.3389/fphar.2024.1298923. eCollection 2024.

Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review.

Pharmacoecon Open. 2024 Sep;8(5):765-772. doi: 10.1007/s41669-024-00496-5. Epub 2024 May 21.

Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?

Pharmacoeconomics. 2024 Aug;42(8):823-827. doi: 10.1007/s40273-024-01393-9. Epub 2024 May 11.

Market access and value-based pricing of digital health applications in Germany.

Cost Eff Resour Alloc. 2022 Jun 13;20(1):25. doi: 10.1186/s12962-022-00359-y.

An integrated valuation model for payer and investor.

J Mark Access Health Policy. 2022 May 29;10(1):2080631. doi: 10.1080/20016689.2022.2080631. eCollection 2022.

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Appl Health Econ Health Policy. 2022 Jul;20(4):501-524. doi: 10.1007/s40258-021-00714-9. Epub 2022 Apr 4.

How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations.

Value Health. 2021 Oct;24(10):1391-1399. doi: 10.1016/j.jval.2021.03.022. Epub 2021 Jul 30.

Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.

Eur J Health Econ. 2022 Mar;23(2):155-163. doi: 10.1007/s10198-021-01276-2. Epub 2021 Jun 9.

本文引用的文献

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.

Value-based differential pricing: efficient prices for drugs in a global context.

Health Econ. 2015 Mar;24(3):294-301. doi: 10.1002/hec.3021. Epub 2013 Dec 11.

What is wrong with orphan drug policies?

Value Health. 2012 Dec;15(8):1185-91. doi: 10.1016/j.jval.2012.09.004.

OFT, VBP: QED?

Health Econ. 2007 Jun;16(6):545-58. doi: 10.1002/hec.1249.

Orphan drugs and the NHS: should we value rarity?

BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016.

The role of economic evaluation in the pricing and reimbursement of medicines.

Health Policy. 1997 Jun;40(3):199-215. doi: 10.1016/s0168-8510(97)00901-9.